Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR

The optimal reduced-intensity conditioning (RIC) regimen for older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (AHCT) remains undefined. We utilized CIBMTR registry data (2013-2022) to compare five common fludarabine-based regimens in 11,731 patients aged ≥50 years: fludarabine combined with 2 days of busulfan (FB2), melphalan 100 mg/m² (FM100), melphalan 140 mg/m² (FM140), or 2 Gy TBI with (FCT) or without (FT) cyclophosphamide. Using propensity score inverse probability weighting and Bayesian Additive Regression Trees (BART), we found that Fludarabine-melphalan (FM) regimens demonstrated superior long-term survival. Although FM140, FCT, and FT showed higher early mortality (≤6 months) than FB2 (P=.036), both FM100 (HR 0.79) and FM140 (HR 0.77) achieved significantly better late (> 6 months) overall survival (OS), outperforming all other regimens (P<.0001). In the 2019-2022 cohort, FM100, FM140, and FCT provided improved disease-free survival (DFS) relative to FB2. Specifically, FM100 yielded superior DFS compared to FCT (P=0.002) and FT (P=0.007). FM-based conditioning consistently resulted in lower relapse rates (P<.0001) and improved late GVHD-free/relapse-free survival. While FM regimens faced higher early non-relapse mortality (NRM), this impact did not persist beyond 6 months. BART analysis confirmed that these survival and relapse benefits remained robust across various patient comorbidities. In conclusion, FM100 and FM140 provide superior long-term survival and DFS for older patients with AML/MDS by providing potent anti-leukemic activity that offsets higher early toxicity. These findings support FM-based RIC as the preferred conditioning platform for this population, regardless of baseline comorbidities.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-11-12
DOI
https://doi.org/10.1182/blood.2026036096
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR

Shatha Farhan, Helene M. Schoemans, Mark Juckett, Lori S. Muffly et al.
Blood
Hematopoietic Stem Cell Transplantation
article

Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR

Shatha Farhan, Helene M. Schoemans, Mark Juckett, Lori S. Muffly, Mohamed Lotfy Sorror, Seth Joshua Rotz, Hany Elmariah, Mariam T. Nawas, Andrew Jay Portuguese, Saurabh Chhabra, Brandon Nuechterlein, Roni Shouval, Reena Jayani, Sairah Ahmed, Michael Richard Grunwald, Michelle Long Schoettler, Betty K. Hamilton, Tania Jain, Ryan J. Stubbins, Wael Saber, Arnon Nagler, Nelli Bejanyan, Veronika Bachanová, Bart Lee Scott, Piyanuch Kongtim, Temitope Oloyede, Xia Bi, Annie Im, Mariam Allbee‐Johnson, Betül Oran, Ryotaro Nakamura, Amy M. Moskop, Bipin N. Savani, Stefan Octavian Ciurea, Soyoung Kim, Poorva Bindal, Rachel Phelan, Brent R. Logan, Andrew C. Peterson, Edward Stadtmauer, Rebecca Higgins
article en

Abstract

The optimal reduced-intensity conditioning (RIC) regimen for older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (AHCT) remains undefined. We utilized CIBMTR registry data (2013-2022) to compare five common fludarabine-based regimens in 11,731 patients aged ≥50 years: fludarabine combined with 2 days of busulfan (FB2), melphalan 100 mg/m² (FM100), melphalan 140 mg/m² (FM140), or 2 Gy TBI with (FCT) or without (FT) cyclophosphamide. Using propensity score inverse probability weighting and Bayesian Additive Regression Trees (BART), we found that Fludarabine-melphalan (FM) regimens demonstrated superior long-term survival. Although FM140, FCT, and FT showed higher early mortality (≤6 months) than FB2 (P=.036), both FM100 (HR 0.79) and FM140 (HR 0.77) achieved significantly better late (> 6 months) overall survival (OS), outperforming all other regimens (P<.0001). In the 2019-2022 cohort, FM100, FM140, and FCT provided improved disease-free survival (DFS) relative to FB2. Specifically, FM100 yielded superior DFS compared to FCT (P=0.002) and FT (P=0.007). FM-based conditioning consistently resulted in lower relapse rates (P<.0001) and improved late GVHD-free/relapse-free survival. While FM regimens faced higher early non-relapse mortality (NRM), this impact did not persist beyond 6 months. BART analysis confirmed that these survival and relapse benefits remained robust across various patient comorbidities. In conclusion, FM100 and FM140 provide superior long-term survival and DFS for older patients with AML/MDS by providing potent anti-leukemic activity that offsets higher early toxicity. These findings support FM-based RIC as the preferred conditioning platform for this population, regardless of baseline comorbidities.

Blood
City Of Hope National Medical Center (US), University of Minnesota (US), Cleveland Clinic (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Vancouver Coastal Health (CA), Johns Hopkins University (US), Thomas Jefferson University (US), Emory University (US), Henry Ford Health System (US), University of Massachusetts Chan Medical School (US), University of Pittsburgh (US), University of Washington (US), University of California, Irvine (US), Medical College of Wisconsin (US), Sheba Medical Center (IL), Universitair Ziekenhuis Leuven (BE), Moffitt Cancer Center (US), University of Chicago (US), University of Chicago Medical Center (US), Fred Hutch Cancer Center (US), Levine Cancer Institute (US), City of Hope (US), Mayo Clinic in Arizona (US), UPMC Hillman Cancer Center (US), University of Pittsburgh Medical Center (US), Children's Healthcare of Atlanta (US), University of Pennsylvania (US), Vanderbilt University Medical Center (US), Stanford University (US)
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon